Mutation analysis in glutaric aciduria type I

Citation
J. Zschocke et al., Mutation analysis in glutaric aciduria type I, J MED GENET, 37(3), 2000, pp. 177-181
Citations number
14
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Molecular Biology & Genetics
Journal title
JOURNAL OF MEDICAL GENETICS
ISSN journal
00222593 → ACNP
Volume
37
Issue
3
Year of publication
2000
Pages
177 - 181
Database
ISI
SICI code
0022-2593(200003)37:3<177:MAIGAT>2.0.ZU;2-1
Abstract
Glutaric aciduria type 1 (GA1), resulting from the genetic deficiency of gl utaryl-CoA dehydrogenase (GDH), is a relatively common cause of acute metab olic brain damage in infants. Encephalopathic crises may be prevented by ca rnitine supplementation and diet, but diagnosis can be difficult as some pa tients do not show the typical excretion of large amounts of glutaric and 3 -hydroxyglutaric acids in the urine. We present a rapid and efficient denat uring gradient gel electrophoresis (DGGE) method for the identification of mutations in the glutaryl-CoA dehydrogenase (GCDH) gene that may be used fo r the molecular diagnosis of GA1 in a routine setting. Using this technique , we identified mutations on both alleles in 48 patients with confirmed GDH deficiency, while no mutations were detected in other patients with clinic al suspicion of GA1 but normal enzyme studies. There was a total of 38 diff erent mutations; 27 mutations were found in single patients only, and 21 mu tations have not been previously reported. Fourteen mutations involved hype rmutable CpG sites. The commonest GA1 mutation in Europeans is R402W which accounts for almost 40% of alleles in patients of German origin. GCDH gene haplotypes were determined through the analysis of polymorphic markers in a ll families, and three CpG mutations were associated with different haploty pes, possibly reflecting independent recurrence. The high sensitivity of th e DGGE method allows the rapid and cost efficient diagnosis of GA1 in insta nces where enzyme analyses are not available or feasible, despite the marke d heterogeneity of the disease.